MedTrace Logo

Ranolazine Mediated PVC Reduction in Ischemic Heart Disease

NCT02360397 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-01-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether ranolazine has beneficial effects on cardiac ischemia through reduction of premature ventricular contraction burden.

Conditions

  • Ventricular Premature Complexes
  • Myocardial Ischemia

Interventions

DRUG

ranolazine

Ranolazine 1000 mg tablet twice daily for 30 days

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Kent Hospital, Rhode Island

    lead OTHER

Principal Investigators

  • Chester M Hedgepeth, MD, PhD · Brigham and Women's Cardiovascular Associates at Care New England

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-12-31
Completion
2018-02-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02360397 on ClinicalTrials.gov